Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 128
- Registration Number
- NCT01588990
- Locations
- 🇦🇺
Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT01587989
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01588002
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT01588184
- Locations
- 🇦🇹
A.Ö. LKH; Abt. für Lungenkrankheiten, Steyr, Austria
🇧🇷Hospital Perola Byington, Sao Paulo, SP, Brazil
🇧🇷Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01585324
A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome
- Conditions
- Down Syndrome
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01580384
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT01579006
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01579019
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: RoActemra/Actemra (tocilizumab)
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT01575769
- Locations
- 🇵🇱
Wojewodzki Szpital Dzieciecy Im. J. Brudzinskiego, Bydgoszcz, Poland
🇷🇺SI Sceintific children health center RAMS, Moscow, Russian Federation
🇷🇺GOU VPO Rostovskiy state medical university Roszdrav, Rostov-na-donu, Russian Federation
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1436
- Registration Number
- NCT01572038
- Locations
- 🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇧🇪UZ Brussel, Brussel, Belgium